{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["21(12)"],"submitter":["Iqbal Z"],"pubmed_abstract":["<h4>Objective</h4>BCR-ABL fusion oncogene is the hallmark of chronic myeloid leukemia (CML), causing genomic instability which leads to accumulation of mutations in BCR-ABL as well as other genes. BCR-ABL mutations are the cause of tyrosine kinase inhibitors (TKIs) resistance in CML. Recently, compound BCR-ABL mutations have been reported to resist all FDA approved TKIs. Therefore, finding novel compound BCR-ABL mutations can help and clinically manage CML. Therefore, our objective was to find out novel drug-resistant compound BCR-ABL mutations in CML and carry out their protein modelling studies.<h4>Methodology</h4>Peripheral blood samples were collected from ten imatinib resistant CML patients receiving nilotinib treatment. BCR-ABL transcript mutations were investigated by employing capi"],"journal":["Asian Pacific journal of cancer prevention : APJCP"],"pagination":["3517-3526"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8046299"],"repository":["biostudies-literature"],"pubmed_title":["Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia."],"pmcid":["PMC8046299"],"pubmed_authors":["Akram AM","Shah IH","Absar M","Karim S","Iqbal J","Jameel A","Alanazi N","Khalid AM","Aljarrah K","Sabar MF","Iqbal Z","Mahmood A","Akhtar T","Khalid M","Mirza Z","Aleem A","Iqbal M","Rasool M"],"additional_accession":[]},"is_claimable":false,"name":"Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.","description":"<h4>Objective</h4>BCR-ABL fusion oncogene is the hallmark of chronic myeloid leukemia (CML), causing genomic instability which leads to accumulation of mutations in BCR-ABL as well as other genes. BCR-ABL mutations are the cause of tyrosine kinase inhibitors (TKIs) resistance in CML. Recently, compound BCR-ABL mutations have been reported to resist all FDA approved TKIs. Therefore, finding novel compound BCR-ABL mutations can help and clinically manage CML. Therefore, our objective was to find out novel drug-resistant compound BCR-ABL mutations in CML and carry out their protein modelling studies.<h4>Methodology</h4>Peripheral blood samples were collected from ten imatinib resistant CML patients receiving nilotinib treatment. BCR-ABL transcript mutations were investigated by employing capi","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Dec","modification":"2025-04-19T17:04:02.214Z","creation":"2022-02-09T16:04:09.812Z"},"accession":"S-EPMC8046299","cross_references":{"pubmed":["33369447"],"doi":["10.31557/APJCP.2020.21.12.3517"]}}